Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Citizens BancShares Inc (FCNCA) vs Nuwellis Inc (NUWE) Price & Performance

First Citizens BancShares IncTrade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

First Citizens BancShares Inc vs Nuwellis Inc — how do they compare? First Citizens BancShares Inc trades at $2,066.27 (market cap $22.95B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: First Citizens BancShares Inc is far larger — about 10431.8× Nuwellis Inc's market cap, and First Citizens BancShares Inc pays a 0.41% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 29 Days and Nuwellis Inc for 26 Days on average.

FCNCANUWE
Market Cap
$22.95B$2.20M
Volume
65,288121,544
Sector
Sector/ThematicHealth
52-Week High
$2.29K$146.65
52-Week Low
$1.64K$0.68
Typical Hold Time
29 Days26 Days
Dividend Yield
0.41%—
Enterprise Value
—-$1.52M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Citizens BancShares Inc

First Citizens BancShares (FCNCA) trades at $2,071.56, down 0.79% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, with a P/E of 11.11 and net income margin of 25.23%, and has beaten EPS estimates for the last three quarters. Recent corporate actions include a $2.10 dividend and expansion through branch acquisitions and new financing initiatives.

The outlook is mixed: solid profitability and earnings beats support upside toward the $2,290 consensus price target, but near-term technical weakness and high institutional hold ratings suggest caution. Key risks include execution of growth initiatives and broader economic pressures on banking.

Nuwellis Inc

NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.

The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FCNCA

No sentiment data available yet.

NUWE
40% Buy60% Sell
Avg holding period · 26 Days

Top news

Latest headlines on both assets

About First Citizens BancShares Inc

First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.

Read more on FCNCA →

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE →